Over 10,000 results
424B4
ABVC
ABVC BioPharma Inc
22 May 24
Prospectus supplement with pricing info
5:00pm
, and the interim analysis of the study is in progress.
Drug: ABV-1601, Major Depression in Cancer Patients, Phase I/II, NCE drug Principal Investigator: Scott … quarter of 2024:
Drug: ABV-1519, Non-Small Cell Lung Cancer treatment, Phase I/II Study in Taiwan, Principal Investigator: Dr. Yung-Hung Luo, M.D
424B3
KRRO
Korro Bio Inc.
22 May 24
Prospectus supplement
4:37pm
be no assurance that RNA editing technologies will not cause undesirable side effects, such as lymphoma, leukemia, or other cancers, or other aberrantly … to the manufacture or distribution of vaccines or medical supplies needed to test or treat patients in a disease outbreak, epidemic or pandemic, this could
424B3
BDRX
Biodexa Pharmaceuticals Plc
22 May 24
Prospectus supplement
4:04pm
with some cancers compared to others. As a result, we may be required to discontinue development of MTX110 for patients with those tumor types … rights are limited to the treatment of brain cancer in humans, administered by convection-enhanced delivery. We received a letter dated June 1, 2020
20-F/A
2022 FY
ETAO
ETAO International Co., Ltd.
22 May 24
Annual report (foreign) (amended)
2:51pm
at various stages (pilot to clinical trials) covering the following diseases: lung/breast cancer, leukemia to type 2 diabetes and alopecia (baldness). We … and to be in compliance with local vaccination and testing policies. While working remotely has proven to be effective to this point, it may eventually inhibit our
424B4
ubn3 3zfb5uodot8
22 May 24
Prospectus supplement with pricing info
2:31pm
8-K
EX-99.1
8yhs8gm6
22 May 24
Arbutus to Present Imdusiran Data at EASL Congress 2024
6:00am
S-1
6tr7x564
21 May 24
IPO registration
5:29pm
8-K
EX-99.1
jzfzi8
21 May 24
Entry into a Material Definitive Agreement
5:23pm
6-K
EX-99.1
qopt21y 6s
21 May 24
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
4:36pm
6-K
EX-99.1
qsdvsdqfy564egs3xk
21 May 24
YS Biopharma Announces Results of Extraordinary General Meeting
4:30pm
424B5
tge53he96w 32wn
21 May 24
Prospectus supplement for primary offering
12:32pm
6-K
EX-99.1
bd62f jnu3e
21 May 24
Current report (foreign)
9:00am
S-1
xaqe31
20 May 24
IPO registration
5:04pm
F-3
ctvc2tl cdbbwlwlnk
20 May 24
Shelf registration (foreign)
4:32pm
F-1/A
e31y8ov
20 May 24
Registration statement (foreign) (amended)
3:53pm
8-K
EX-99.1
zqqf3t2 ak0ldq1bdbpd
20 May 24
Regulation FD Disclosure
9:25am